Biosensors International Group, Ltd
Debashis Dutta has had an extensive career in the medical industry, with diverse roles and responsibilities. Debashis started their career at Guidant Corporation in 1996, where they served as a Principal R&D Engineer for four years. In 2000, they joined Avantec Vascular Corporation as Manager, R&D. After three years, they moved on to Biosensors International Group, Ltd, where they held various positions of increasing responsibility, including Director, Research and Development, Senior Director, Research and Development, Vice President, Research and Development, Vice President, Quality Assurance and Advanced R&D, and most recently, Vice President, Scientific Affairs. Debashis Dutta's work experience demonstrates their expertise and leadership in scientific research and development, quality assurance, and advanced technologies in the medical field.
Debashis Dutta's education history includes studying at the University of Connecticut, where they pursued a Doctor of Philosophy (Ph.D.) degree in Polymer Science. However, specific information regarding the start and end years of their education is not provided.
This person is not in any offices
Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets pioneering interventional cardiology devices. The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system. BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark LEADERS FREE trial and features a selectively micro-structured abluminal surface allowing polymer & carrier free delivery of BA9™. Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of the company New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system. Together, Biosensors and NVT will leverage our their respective innovative expertise in Cardiovascular and Structural Heart technologies. Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation. Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.